Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.
Identifieur interne : 001402 ( PubMed/Curation ); précédent : 001401; suivant : 001403Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.
Auteurs : J L Baulieu [France] ; M J Ribeiro ; C. Levilion-Prunier ; F. Tranquart ; J R Chartier ; D. Guilloteau ; J P Cottier ; J C Besnard ; L. Pourcelot ; A. AutretSource :
- Nuclear medicine communications [ 0143-3636 ] ; 1999.
English descriptors
- KwdEn :
- Adult, Aged, Basal Ganglia Diseases (diagnostic imaging), Basal Ganglia Diseases (metabolism), Brain (diagnostic imaging), Brain Chemistry, Caudate Nucleus (chemistry), Caudate Nucleus (diagnostic imaging), Corpus Striatum (chemistry), Corpus Striatum (diagnostic imaging), Cysteine (analogs & derivatives), Female, Frontal Lobe (chemistry), Frontal Lobe (diagnostic imaging), Humans, Iodine Radioisotopes, Lisuride (analogs & derivatives), Male, Occipital Lobe (chemistry), Occipital Lobe (diagnostic imaging), Organotechnetium Compounds, Parkinson Disease (diagnostic imaging), Parkinson Disease (metabolism), Perfusion, Radiopharmaceuticals, Receptors, Dopamine D2 (analysis), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , analogs & derivatives : Cysteine, Lisuride.
- chemical , analysis : Receptors, Dopamine D2.
- chemistry : Caudate Nucleus, Corpus Striatum, Frontal Lobe, Occipital Lobe.
- diagnostic imaging : Basal Ganglia Diseases, Brain, Caudate Nucleus, Corpus Striatum, Frontal Lobe, Occipital Lobe, Parkinson Disease.
- metabolism : Basal Ganglia Diseases, Parkinson Disease.
- Adult, Aged, Brain Chemistry, Female, Humans, Iodine Radioisotopes, Male, Organotechnetium Compounds, Perfusion, Radiopharmaceuticals, Tomography, Emission-Computed, Single-Photon.
Abstract
Various parameters are currently used for the semi-quantitative assessment of dopamine D2 receptors and differ according to the delineation of the striatal region of interest (ROI) and the choice of the reference ROI. The aim of this study was to assess the value of different ROI approaches in differentiating patients with normal or increased numbers of D2 dopamine receptors (group 1 = Parkinson's disease, n = 8) from patients with decreased dopamine D2 receptors (group 2 = other extrapyramidal syndromes, n = 9) using 123I-iodolisuride SPET (ILIS-SPET). 123I-iodolisuride (190 +/- 31 MBq) and 99Tcm-ethyl cysteinate dimer (99Tcm-ECD) perfusion SPET were performed in the same position, with a dual-headed gamera camera equipped with fan beam collimators. Both a geometric approach (ellipse, circle or rectangle) and an anatomical approach using the CT scan and perfusion SPET as anatomical guides were used to draw striatal and reference ROIs. A total of 33 different parameters were calculated for each patient, indicating the ratio of counts between the striatal and reference ROIs (frontal, occipital cortex or cerebellum) and the asymmetry between the right and left striatum. More significant differences between group 1 and group 2 were found by using geometric ROIs than by using anatomical ROIs. The most discriminant ratios were the caudate/occipital, caudate/frontal and striatum/occipital ratios (P = 0.001, P = 0.002, P = 0.003 respectively). A close correlation was found between the striatum/caudate and striatum/occipital ratios, but not between the striatum/frontal and striatum/occipital ratios or between the striatum/frontal and striatum/caudate ratios. We conclude that the occipital cortex is the best reference for the semi-quantitative evaluation of dopamine D2 receptors as the frontal cortex could include some dopamine D2 receptor-bound radioligand, and that the caudate/occipital ratio is an appropriate parameter for differentiating Parkinson's disease from non-Parkinson extrapyramidal syndrome by 123I-iodolisuride SPET.
PubMed: 9949416
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001443
Links to Exploration step
pubmed:9949416Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.</title><author><name sortKey="Baulieu, J L" sort="Baulieu, J L" uniqKey="Baulieu J" first="J L" last="Baulieu">J L Baulieu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, INSERM U316, CHU Tours, France. baulieu@med.univtours.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, INSERM U316, CHU Tours</wicri:regionArea></affiliation></author><author><name sortKey="Ribeiro, M J" sort="Ribeiro, M J" uniqKey="Ribeiro M" first="M J" last="Ribeiro">M J Ribeiro</name></author><author><name sortKey="Levilion Prunier, C" sort="Levilion Prunier, C" uniqKey="Levilion Prunier C" first="C" last="Levilion-Prunier">C. Levilion-Prunier</name></author><author><name sortKey="Tranquart, F" sort="Tranquart, F" uniqKey="Tranquart F" first="F" last="Tranquart">F. Tranquart</name></author><author><name sortKey="Chartier, J R" sort="Chartier, J R" uniqKey="Chartier J" first="J R" last="Chartier">J R Chartier</name></author><author><name sortKey="Guilloteau, D" sort="Guilloteau, D" uniqKey="Guilloteau D" first="D" last="Guilloteau">D. Guilloteau</name></author><author><name sortKey="Cottier, J P" sort="Cottier, J P" uniqKey="Cottier J" first="J P" last="Cottier">J P Cottier</name></author><author><name sortKey="Besnard, J C" sort="Besnard, J C" uniqKey="Besnard J" first="J C" last="Besnard">J C Besnard</name></author><author><name sortKey="Pourcelot, L" sort="Pourcelot, L" uniqKey="Pourcelot L" first="L" last="Pourcelot">L. Pourcelot</name></author><author><name sortKey="Autret, A" sort="Autret, A" uniqKey="Autret A" first="A" last="Autret">A. Autret</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:9949416</idno><idno type="pmid">9949416</idno><idno type="wicri:Area/PubMed/Corpus">001443</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001443</idno><idno type="wicri:Area/PubMed/Curation">001402</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001402</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.</title><author><name sortKey="Baulieu, J L" sort="Baulieu, J L" uniqKey="Baulieu J" first="J L" last="Baulieu">J L Baulieu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, INSERM U316, CHU Tours, France. baulieu@med.univtours.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, INSERM U316, CHU Tours</wicri:regionArea></affiliation></author><author><name sortKey="Ribeiro, M J" sort="Ribeiro, M J" uniqKey="Ribeiro M" first="M J" last="Ribeiro">M J Ribeiro</name></author><author><name sortKey="Levilion Prunier, C" sort="Levilion Prunier, C" uniqKey="Levilion Prunier C" first="C" last="Levilion-Prunier">C. Levilion-Prunier</name></author><author><name sortKey="Tranquart, F" sort="Tranquart, F" uniqKey="Tranquart F" first="F" last="Tranquart">F. Tranquart</name></author><author><name sortKey="Chartier, J R" sort="Chartier, J R" uniqKey="Chartier J" first="J R" last="Chartier">J R Chartier</name></author><author><name sortKey="Guilloteau, D" sort="Guilloteau, D" uniqKey="Guilloteau D" first="D" last="Guilloteau">D. Guilloteau</name></author><author><name sortKey="Cottier, J P" sort="Cottier, J P" uniqKey="Cottier J" first="J P" last="Cottier">J P Cottier</name></author><author><name sortKey="Besnard, J C" sort="Besnard, J C" uniqKey="Besnard J" first="J C" last="Besnard">J C Besnard</name></author><author><name sortKey="Pourcelot, L" sort="Pourcelot, L" uniqKey="Pourcelot L" first="L" last="Pourcelot">L. Pourcelot</name></author><author><name sortKey="Autret, A" sort="Autret, A" uniqKey="Autret A" first="A" last="Autret">A. Autret</name></author></analytic><series><title level="j">Nuclear medicine communications</title><idno type="ISSN">0143-3636</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Basal Ganglia Diseases (diagnostic imaging)</term><term>Basal Ganglia Diseases (metabolism)</term><term>Brain (diagnostic imaging)</term><term>Brain Chemistry</term><term>Caudate Nucleus (chemistry)</term><term>Caudate Nucleus (diagnostic imaging)</term><term>Corpus Striatum (chemistry)</term><term>Corpus Striatum (diagnostic imaging)</term><term>Cysteine (analogs & derivatives)</term><term>Female</term><term>Frontal Lobe (chemistry)</term><term>Frontal Lobe (diagnostic imaging)</term><term>Humans</term><term>Iodine Radioisotopes</term><term>Lisuride (analogs & derivatives)</term><term>Male</term><term>Occipital Lobe (chemistry)</term><term>Occipital Lobe (diagnostic imaging)</term><term>Organotechnetium Compounds</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (metabolism)</term><term>Perfusion</term><term>Radiopharmaceuticals</term><term>Receptors, Dopamine D2 (analysis)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cysteine</term><term>Lisuride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Caudate Nucleus</term><term>Corpus Striatum</term><term>Frontal Lobe</term><term>Occipital Lobe</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Brain</term><term>Caudate Nucleus</term><term>Corpus Striatum</term><term>Frontal Lobe</term><term>Occipital Lobe</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Brain Chemistry</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes</term><term>Male</term><term>Organotechnetium Compounds</term><term>Perfusion</term><term>Radiopharmaceuticals</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Various parameters are currently used for the semi-quantitative assessment of dopamine D2 receptors and differ according to the delineation of the striatal region of interest (ROI) and the choice of the reference ROI. The aim of this study was to assess the value of different ROI approaches in differentiating patients with normal or increased numbers of D2 dopamine receptors (group 1 = Parkinson's disease, n = 8) from patients with decreased dopamine D2 receptors (group 2 = other extrapyramidal syndromes, n = 9) using 123I-iodolisuride SPET (ILIS-SPET). 123I-iodolisuride (190 +/- 31 MBq) and 99Tcm-ethyl cysteinate dimer (99Tcm-ECD) perfusion SPET were performed in the same position, with a dual-headed gamera camera equipped with fan beam collimators. Both a geometric approach (ellipse, circle or rectangle) and an anatomical approach using the CT scan and perfusion SPET as anatomical guides were used to draw striatal and reference ROIs. A total of 33 different parameters were calculated for each patient, indicating the ratio of counts between the striatal and reference ROIs (frontal, occipital cortex or cerebellum) and the asymmetry between the right and left striatum. More significant differences between group 1 and group 2 were found by using geometric ROIs than by using anatomical ROIs. The most discriminant ratios were the caudate/occipital, caudate/frontal and striatum/occipital ratios (P = 0.001, P = 0.002, P = 0.003 respectively). A close correlation was found between the striatum/caudate and striatum/occipital ratios, but not between the striatum/frontal and striatum/occipital ratios or between the striatum/frontal and striatum/caudate ratios. We conclude that the occipital cortex is the best reference for the semi-quantitative evaluation of dopamine D2 receptors as the frontal cortex could include some dopamine D2 receptor-bound radioligand, and that the caudate/occipital ratio is an appropriate parameter for differentiating Parkinson's disease from non-Parkinson extrapyramidal syndrome by 123I-iodolisuride SPET.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9949416</PMID><DateCreated><Year>1999</Year><Month>06</Month><Day>11</Day></DateCreated><DateCompleted><Year>1999</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0143-3636</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nuclear medicine communications</Title><ISOAbbreviation>Nucl Med Commun</ISOAbbreviation></Journal><ArticleTitle>Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.</ArticleTitle><Pagination><MedlinePgn>77-84</MedlinePgn></Pagination><Abstract><AbstractText>Various parameters are currently used for the semi-quantitative assessment of dopamine D2 receptors and differ according to the delineation of the striatal region of interest (ROI) and the choice of the reference ROI. The aim of this study was to assess the value of different ROI approaches in differentiating patients with normal or increased numbers of D2 dopamine receptors (group 1 = Parkinson's disease, n = 8) from patients with decreased dopamine D2 receptors (group 2 = other extrapyramidal syndromes, n = 9) using 123I-iodolisuride SPET (ILIS-SPET). 123I-iodolisuride (190 +/- 31 MBq) and 99Tcm-ethyl cysteinate dimer (99Tcm-ECD) perfusion SPET were performed in the same position, with a dual-headed gamera camera equipped with fan beam collimators. Both a geometric approach (ellipse, circle or rectangle) and an anatomical approach using the CT scan and perfusion SPET as anatomical guides were used to draw striatal and reference ROIs. A total of 33 different parameters were calculated for each patient, indicating the ratio of counts between the striatal and reference ROIs (frontal, occipital cortex or cerebellum) and the asymmetry between the right and left striatum. More significant differences between group 1 and group 2 were found by using geometric ROIs than by using anatomical ROIs. The most discriminant ratios were the caudate/occipital, caudate/frontal and striatum/occipital ratios (P = 0.001, P = 0.002, P = 0.003 respectively). A close correlation was found between the striatum/caudate and striatum/occipital ratios, but not between the striatum/frontal and striatum/occipital ratios or between the striatum/frontal and striatum/caudate ratios. We conclude that the occipital cortex is the best reference for the semi-quantitative evaluation of dopamine D2 receptors as the frontal cortex could include some dopamine D2 receptor-bound radioligand, and that the caudate/occipital ratio is an appropriate parameter for differentiating Parkinson's disease from non-Parkinson extrapyramidal syndrome by 123I-iodolisuride SPET.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baulieu</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, INSERM U316, CHU Tours, France. baulieu@med.univtours.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Levilion-Prunier</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tranquart</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Chartier</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Guilloteau</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cottier</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Besnard</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Pourcelot</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Autret</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nucl Med Commun</MedlineTA><NlmUniqueID>8201017</NlmUniqueID><ISSNLinking>0143-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015609">Organotechnetium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075786">iodolisuride</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0QN3D755O</RegistryNumber><NameOfSubstance UI="D008090">Lisuride</NameOfSubstance></Chemical><Chemical><RegistryNumber>H25WJA31XE</RegistryNumber><NameOfSubstance UI="C059659">technetium Tc 99m bicisate</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008090" MajorTopicYN="N">Lisuride</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009778" MajorTopicYN="N">Occipital Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015609" MajorTopicYN="N">Organotechnetium Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="N">Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>2</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>2</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9949416</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001402 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001402 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9949416
|texte= Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9949416" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |